KRAS and neoplasm: Comparing the OS of patients with and without KRAS mutation in tumor tissue, no statistically significant difference was achieved (median OS 184 days, 95% CI: 31–474 vs. 296 days, 95% CI: 31–474, p = 0.3251, Figure 2a).